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Abstract
Objective: The pathogenic mitochondrial DNA m.3243A>G mutation is associ-
ated with a wide range of clinical features, making disease prognosis extremely
difficult to predict. We aimed to understand the cause of this heterogeneity.
Methods: We examined the phenotypic profile of 238 adult m.3243A>G carri-
ers (patients and asymptomatic carriers) from the UK MRC Mitochondrial Dis-
ease Patient Cohort using the Newcastle Mitochondrial Disease Adult Scale. We
modeled the role of risk factors for the development of specific phenotypes
using proportional odds logistic regression. As mitochondria are under the dual
control of their own and the nuclear genome, we examined the role of additive
nuclear genetic factors in the development of these phenotypes within 46 pedi-
grees from the cohort. Results: Seizures and stroke-like episodes affect 25% and
17% of patients, respectively; more common features include hearing impair-
ment, gastrointestinal disturbance, psychiatric involvement, and ataxia. Age,
age-adjusted blood heteroplasmy levels, and sex are poor predictors of pheno-
typic severity. Hearing impairment, diabetes, and encephalopathy show the
strongest associations, but pseudo-R2 values are low (0.14–0.17). We found a
high heritability estimate for psychiatric involvement (h2=0.76, P = 0.0003) and
moderate estimates for cognition (h2=0.46, P = 0.0021), ataxia (h2 = 0.45,
P = 0.0011), migraine (h2 = 0.41, P = 0.0138), and hearing impairment (h2 = 0.40,
P = 0.0050). Interpretation: Our results provide good evidence for the presence
of nuclear genetic factors influencing clinical outcomes in m.3234A>G-related
disease, paving the way for future work identifying these through large-scale
genetic linkage and association studies, increasing our understanding of the
pathogenicity of m.3243A>G and providing improved estimates of prognosis.
Introduction
Mitochondria, essential organelles responsible for oxida-
tive phosphorylation (OXPHOS), are under the dual con-
trol of their own and the nuclear genome. Mitochondrial
DNA (mtDNA) encodes 13 subunits of the OXPHOS sys-
tem, along with 22 mitochondrial tRNAs and two mitori-
bosomal subunits.1 An additional ~1150 proteins are
nuclear-encoded, including further OXPHOS subunits
and proteins related to other essential mitochondrial
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functions.2 Mutations in nuclear and mtDNA are respon-
sible for a clinically heterogeneous group of mitochon-
drial diseases.3
To explore the cause of this heterogeneity, we studied the
pathogenic m.3243A>G mtDNA variant within MT-TL1
(encoding mitochondrial tRNALeu(UUR)), which represents
the most common heteroplasmic mtDNA disease geno-
type.3–6 About 15% m.3243A>G patients present with mito-
chondrial encephalopathy, lactic acidosis, and stroke-like
episodes (MELAS) syndrome; the remainder display a wide
variety of clinical features including diabetes, deafness, atax-
ia, and isolated myopathy.7 Population-based studies esti-
mate a carrier frequency of 140–250 per 100,000, whereas
the estimated disease prevalence is 40–70 times lower.5,6,8
Therefore, many carriers are clinically asymptomatic or have
mild disease not recognized as mitochondrial.
Heteroplasmy describes the coexistence of mutant and
wild-type mtDNA molecules within the same cell.
mtDNA mutant levels can vary dramatically between
different individuals and tissues; postmitotic tissues such
as muscle have higher levels, whilst levels in blood
decrease significantly over time.4,9–11 Heteroplasmy con-
tributes to, but does not fully explain, the observed
heterogeneity.12–14 Patients with identical tissue
m.3243A>G heteroplasmy levels can exhibit very different
symptoms, and some patients with high heteroplasmy
levels are relatively asymptomatic. Disease progression in
patients with single, large-scale mtDNA deletions can be
predicted using percentage mutation load, deletion size,
and genomic position.15 However, heteroplasmy and age
are only weakly correlated with m.3243A>G-related dis-
ease severity and cannot be used to predict key clinical
outcomes such as stroke-like episodes.15 Therefore, coun-
seling patients regarding their likely prognosis and female
carriers regarding risk to future offspring is enormously
problematic.
Such unexplained heterogeneity suggests that unidenti-
fied factors influence phenotype; the nuclear genome is a
strong candidate given the interaction between the two
genomes. Nuclear background has been shown to influ-
ence mitochondrial function, with a mouse model show-
ing decreased fitness and lifespan when mitochondrial
and nuclear mutations are combined.16 A recent report
describing two pairs of monozygotic twins highlighted a
strikingly similar clinical phenotype, age-of-onset, and tis-
sue m.3243A>G heteroplasmy levels in each pair.17 Fur-
thermore, there is evidence for the presence of nuclear
modifiers in other maternally inherited mtDNA muta-
tions in humans18 and the control of mtDNA segregation
in mice.19
The extent to which genetic factors contribute to a
phenotype can be assessed using familial relationships to
estimate heritability.20 This represents the proportion of
trait variance that can be attributed to inherited genetic
factors, therefore prioritizing traits for further genetic
analysis.
We aimed to model the development of specific
m.3243A>G-related phenotypes within a large UK patient
cohort to allow the prediction of disease prognosis in
patients. We examined the role of age, heteroplasmy, and
sex as risk factors and evaluated the potential role of
additive nuclear genetic factors by exploiting familial rela-
tionships to generate estimates of heritability.
Materials and methods
Study population
These studies were undertaken using data from
238 m.3243A>G carriers from the MRC Mitochondrial
Disease Patient Cohort UK.7 All individuals were
reviewed and investigated by the NHS Highly Specialised
Service for Rare Mitochondrial Disorders of Adults and
Children in Newcastle upon Tyne. Patient follow-up was
carried out (median interval = 1.11 years, IQR = 0.73)
using the Newcastle Mitochondrial Disease Adult Scale
(NMDAS), a validated scale to evaluate multisystem
involvement and disease burden in adult mitochondrial
disease.22 Recruitment is ongoing; here we describe the
current phenotypic profile of the cohort, which displays a
wide spectrum of disease (median total NMDAS = 19.5,
IQR = 25.9, range = 0–104). In our analyses, we have
included 202 symptomatic patients (total NMDAS score
≥5), 32 relatively asymptomatic carriers (NMDAS <5 with
a detectable m.3243A>G mutation), and 4 with incom-
plete NMDAS data.
The median age at last assessment was 43.4 years
(IQR = 23.2, range = 15.1–79.9), and only two individuals
were <18 years old. For the patients with multiple NMDAS
assessments (N = 175), the median follow-up time was
3.60 years (IQR = 4.99, range = 0.05–11.90) with a med-
ian of 4 assessments per patient (IQR = 5, max 17).
NMDAS and blood m.3243A>G heteroplasmy data
were available for 219 subjects (132 females); 157 of
these were from families with multiple members within
the cohort, comprising 46 familial lineages with multiple
members, and 62 individuals who had no relatives in
the cohort. Pedigrees range in size from two to seven
individuals (median 3, IQR = 2), and span 2–4 genera-
tions.
Ethical approval was granted by the Newcastle and
North Tyneside Research Ethics Committee (13/NE/
0326), and written informed consent from patients was
obtained prior to study inclusion. All clinical investiga-
tions were evaluated according to the Declaration of
Helsinki.
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Phenotypes
Nineteen questions from the NMDAS (http://www.newca
stle-mitochondria.com/clinical-professional-home-page/
clinical-publications/nmdas/) were considered. Section I
of NMDAS scores current function according to patients
and/or caregiver interview and relates to the preceding
4 weeks. Most questions from this NMDAS section were
omitted from these analyses due to their subjective nat-
ure. The exception was hearing impairment which was
included as it is one of the common symptoms for
m.3243A>G-related disease, and is the only question that
captures information about hearing. All questions are
independently assessed; therefore, the exclusion of ques-
tions does not affect the validity of the sections that
were retained in the study. Section II scores system
specific involvement according to patients and/or care-
giver interview and consultation with medical notes and
relates to the preceding 12-month period and section
III scores current clinical assessment according to an
examination performed at the time of assessment; both
are likely to be more objective and so all were included.
Some traits, such as stroke-like episodes, can be
stochastic in nature; individuals can score very low on
one assessment despite historically high scores. There-
fore, to ensure we captured these historical events, a
single independent point for each trait and each indi-
vidual was determined by the maximal NMDAS score
and the youngest age at which that score was attained.
For asymptomatic individuals, the age at the most
recent assessment was used.
Heteroplasmy measurements
Total DNA was extracted from whole blood by standard
procedures. Pyrosequencing on the Pyromark Q24 plat-
form permitted quantification of m.3243A>G hetero-
plasmy levels, as previously described and validated,22
with mutation-specific pyrosequencing primers according
to GenBank Accession number NC_012920.1: 50biotiny-
lated forward: m.3143-3163; reverse: m.3331-3353; and
reverse pyrosequencing primer: m.3244-3258 (IDT, Coral-
ville). The allele quantification application of Pyromark’s
proprietary Q24 software was used to calculate hetero-
plasmy levels (level of test sensitivity >3% mutant
mtDNA).
In blood, the m.3243A>G heteroplasmy level progressively
declines by ~2.3% year1 and recent work has shown that
age-corrected blood heteroplasmy is a better predictor for
disease progression than mean urine heteroplasmy levels and
sex-corrected mean urine heteroplasmy levels (unpub-
lished data). Given this exponential decline, m.3243A>G
levels were corrected for age using the following formula:
Age-adjusted blood level = Blood heteroplasmy/0.977(age+12)
The median age-adjusted blood heteroplasmy level was
60.1% (IQR = 53.9, range = 2.1–100).
Statistical analysis
Pearson correlations between traits and significance levels
were calculated using the rcorr function in the Hmisc pack-
age in R.24,25
Specific phenotypic feature analysis used proportional
odds multiple logistic regression, with age, age-adjusted
mean blood heteroplasmy, and sex as predictors, using
clm from the ordinal package in R.23,25 Sex was dropped
from the model when the significance threshold
(P = 0.05, determined by maximum likelihood testing)
was not reached. This was the case for all phenotypes
except ptosis, myopathy, and gastrointestinal disturbance.
NMDAS scores were re-categorized as asymptomatic/mild
(NMDAS = 0–1), moderate (2–3), and severe (4–5) to
ensure sufficient patients in each group for statistical
modeling.
Assumptions of the proportional odds model were
tested by comparing fitted models with models where the
effects were modeled as nominal rather than ordinal,
using a likelihood ratio test and a significance threshold
of P = 0.05. Encephalopathy did not meet the assumption
of proportional odds so was considered as a binary trait
using threshold scores determined a priori based on the
NMDAS clinical descriptors,21 using clinical judgement
and ensuring a minimum of 30 subjects in the affected
group (Table 1). Due to small numbers, extrapyramidal
involvement was also considered as a binary trait with
moderate and severe scores (NMDAS = 2–5) combined
into one category.
We report McFadden’s pseudo-R2 values,26 which esti-
mate the proportion of observed variance described by
the fitted model. This is defined by 1log(Lc)/log(Lnull),
where Lc is the maximum likelihood of the fitted model
and Lnull is the maximum likelihood of the null.
Odds ratios (relating to decades for age and 10%
change in level for heteroplasmy) were calculated by tak-
ing exponentials of the coefficients estimated by the
model. They represent the odds that an individual will
move from one category to the next (asymptomatic/mild
to moderate or moderate to severe) given an increase of a
decade (age) or 10% (heteroplasmy) in the predictor vari-
ables, compared to the odds in the absence of an
increase.
Unless otherwise stated, we report unadjusted P values
as for reasons well documented in the literature, Bonfer-
roni correction would be too conservative, particularly as
we are testing a priori hypotheses with variables that are
not all independent.27
ª 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. 3
S. J. Pickett et al. Nuclear Factors in m.3243A>G-related Disease
Calculation of heritability
Heritability in the narrow sense (h2) is the proportion of
the total population variance of a trait (r2p) that can be
attributed to additive nuclear genetic effects (r2a), expressed
as a ratio (h2 ¼ r2a=r2p). Heritability was estimated using
variance components methods and significance levels
obtained using likelihood ratio tests, as implemented in the
SOLAR software package (SOLAR Eclipse version 8.1.1).28
Results were corrected for ascertainment bias by condition-
ing on proband status, as implemented in SOLAR. This
information was available for 38 pedigrees; data from pro-
bands in the remaining 14 pedigrees were not available due
to death before the study began.
To produce heritability estimates which excluded the
variation due to known factors such as age and hetero-
plasmy level, we included these factors as covariates in
these analyses. Sex was included where it was shown to
have an effect at the P < 0.1 level (migraine, dysphonia-
dysarthria, ptosis, gastrointestinal disturbance, and
myopathy). The square root of trait score was used for
cerebellar ataxia, neuropathy, dysphonia–dysarthria,
encephalopathy, stroke-like episodes, visual acuity, and
chronic progressive external ophthalmoplegia (CPEO), in
order to ensure normality of the residuals (kurtosis <0.8).
After this transformation, only stroke-like episodes and
encephalopathy showed residual kurtosis outside of the
acceptable range, and this is likely to be due to the small
number of affected individuals for these traits. Pyramidal
and extrapyramidal involvements were excluded from
the heritability analysis due to low numbers of affected
individuals.
For binary trait analysis, individuals with a score
greater than or equal to a threshold score (Table 1)
were coded as affected, all others as unaffected. For
stroke-like episodes, only those patients with radiologi-
cally confirmed stroke-like episodes were coded as
affected. We report heritabilities (h2), standard error
(SE), P values, and Kullback-Leibler R2, as calculated in
SOLAR.28 Models for neuropathy, seizures, gastrointesti-
nal disturbance, and myopathy did not converge and so
are not presented.
To determine whether common genetic factors influ-
ence pairs of traits, bivariate heritability analysis was per-
formed. SOLAR calculates the estimated genetic
correlation (rhoG), a measure of the shared genetic vari-
ance between traits (pleiotropy). Significant (determined
by likelihood ratio test) genetic correlations suggest the
presence of common genetic factors (one or more genes)
that influence both traits.29
Table 1. NMDAS traits including threshold values for analysis as binary traits.
Trait Threshold score Phenotype description NMDAS section
Psychiatric involvement 3 Moderate to severe, warranting specialist treatment II
Cerebellar ataxia 2 At least unable to maintain heel-toe walking or displaying
mild unilateral dysmetria
III
Migraine 5 Four days per month or more II
Cognition 3 Combined centiles of 29 or below on Wechsler Test
of Adult Reading, Symbol Search and Speed of Comprehension Test
III
Neuropathy 2 At least sensory impairment (e.g., glove and stocking sensory loss) III
Dysphonia-dysarthria 2 Showing at least mild impairment (clear impairment but easily understood) III
Seizures 1 At least past history of epilepsy II
Encephalopathy 1 At least past history of encephalopathy II
Stroke-like episodes 1 At least transient focal sensory symptoms II
Visual acuity 3 Combined Snellen fraction > 6/36 III
Ptosis 2 At least unilateral ptosis obscuring 1/3 of pupil III
CPEO 2 Abduction of at least one eye incomplete III
Hearing impairment 3 At least moderate deafness (e.g. regularly requiring repetition),
not fully corrected with hearing aid
I
Gastrointestinal disturbance 4 Dysmotility requiring admission or persistent and/or recurrent
anorexia/vomiting/weight loss
II
Myopathy 2 Mild but clear proximal weakness in hip flexion and shoulder
abduction and minimal weakness in elbow flexion and knee extension
III
Diabetes 2 At least impaired glucose tolerance (in absence of intercurrent illness) II
Cardiovascular involvement 2 At least asymptomatic left ventricular hypertrophy on echo
or nonsustained brady/tachyarrhythmia on ECG
II
Thresholds were defined based on the NMDAS clinical descriptors for each trait, to ensure traits were as objective as possible.
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Results
Marked clinical variation in the phenotypic
profile of the m.3243A>G cohort
First, we examined the range of clinical phenotypes observed
in our patient cohort, as assessed by the NMDAS. The most
common phenotypic traits associated with the pathogenic
m.3243A>G variant are hearing impairment (81%;
NMDAS≥1) and gastrointestinal disturbance (76%), followed
by psychiatric involvement (69%) and cerebellar ataxia
(66%) (Fig. 1). Half of our patients exhibit mild psychiatric
involvement (e.g., reactive depression, NMDAS=1/2), but
19% demonstrate a moderate to severe disorder
(NMDAS=3/4/5). Seizures, encephalopathy, and stroke-like
episodes affect 25%, 21%, and 17% of patients respectfully.
Both pyramidal and extrapyramidal involvements are rare in
the cohort at 13% and 5% respectively. We also inspected
the distribution of NMDAS scores (Fig. 1). For hearing
impairment, the distribution is reasonably uniform, in com-
parison with cerebellar ataxia where each successive level of
severity is progressively rarer in the cohort. Diabetes and
stroke-like episodes demonstrate bi-modal distributions, with
patients generally either asymptomatic or severely affected.
Figure 1. Phenotypic profile of the cohort. For each trait, the maximum score attained by each patient in any NMDAS assessment was noted.
The total number of patients assessed for each trait ranges from 214 to 237.
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A number of phenotypic traits are
correlated
We then asked whether traits commonly observed in asso-
ciation with the pathogenic m.3243A>G variant are corre-
lated with each other, which would provide evidence of a
common underlying etiology (Fig. 2). Unsurprisingly, sei-
zures, encephalopathy, and stroke-like episodes are well
correlated (estimated Pearson correlation coefficient (r)
range ~ 0.69–0.83) and so are ptosis and CPEO (r ~ 0.62).
Hearing impairment and diabetes are moderately corre-
lated (r ~ 0.45), confirming a well-reported association
between these two traits.30 Cognition shows moderate to
strong correlations with other CNS traits, such as dyspho-
nia–dysarthria, seizures, stroke-like episodes, encephalopa-
thy, seizures, and cerebellar ataxia (r ~ 0.52–0.59).
Cerebellar ataxia is correlated with a number of traits,
notably myopathy (r ~ 0.76), hearing impairment
(r ~ 0.63), and dysphonia–dysarthria (r ~ 0.68).
Interestingly, both migraine and diabetes are only cor-
related with a small number of other traits. Migraine is,
however, moderately correlated with gastrointestinal dis-
turbance (r ~ 0.45).
Age, heteroplasmy, and sex are poor
predictors of phenotypic severity
Next, we explored the impact of age, heteroplasmy level,
and sex on the severity of specific phenotypic features
using proportional odds logistic regression (Fig. 3). Odds
ratios (ORs; relating to decades for age and 10% change
in level for heteroplasmy) show the clinical effect size of
Figure 2. Heat map showing correlations between trait scores. Estimated Pearson correlation coefficients (r) are shown where the test reached a
Bonferroni adjusted significance threshold of P = 0.00029 (0.05/171).
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each factor. Higher severity of diabetes (OR = 2.14,
P = 1.5 9 108), hearing impairment (OR = 1.95,
P = 4.7 9 109), cerebellar ataxia (OR = 1.88, P = 3.2 9
107), and neuropathy (OR = 1.51, P = 2.5 9 102) are
most strongly associated with increasing age, consistent
with the clinical picture of a progressive disease. Almost
all features were significantly associated with higher
heteroplasmy, the most strongly associated being hearing
impairment (OR = 1.47, P = 7.2 9 1013), dysphonia–
dysarthria (OR = 1.39, P = 2.8 9 105), diabetes
(OR = 1.37, P = 5.7 9 108), stroke-like episodes (OR =
1.28, P = 1.0 9 103), cerebellar ataxia (OR = 1.27,
P = 8.6 9 106), myopathy (OR = 1.26, P = 2.2 9 105),
cardiovascular involvement (OR = 1.25, P = 1.0 9 104),
and encephalopathy (OR = 1.24, P = 6.0 9 104).
Although McFadden’s pseudo-R2 values indicate that hear-
ing impairment (0.17, P = 2.5 9 1017), diabetes (0.16,
P = 4.1 9 1013), and cerebellar ataxia (0.12,
P = 1.8 9 109) show the strongest association between
higher phenotypic severity, higher age-adjusted blood
heteroplasmy, and increasing age, pseudo-R2 values are
low, highlighting the limited predictive power of these
covariates.
Several key features of the MELAS phenotype, includ-
ing stroke-like episodes, seizures, and encephalopathy,
were not associated with age, only with heteroplasmy.
This is consistent with clinical observations.
For two phenotypes, the effect of sex was significant
(ptosis; ORmales = 3.02, P = 2.6 9 10
3 and myopathy;
ORmales = 0.43, P = 7.9 9 10
3). Although more males
(17/95, 17.9%) were affected by stroke-like episodes than
females (15/144, 10.4%), this did not reach significance
(Fisher’s exact test, P = 0.12).
m.3243A>G-related phenotypes are
heritable
As low pseudo-R2 values indicate that a large propor-
tion of the phenotypic variance remains to be
explained, we then explored the likelihood of nuclear
genetic factors contributing to phenotypic variance in
our cohort by calculating heritability (h2) of NMDAS
traits using the information contained within pedigree
structures.
We found a significant, high heritability estimate for
psychiatric involvement (h2=0.76, P = 0.0003) and mod-
erate estimates for cognition (h2 = 0.46, P = 0.0021),
cerebellar ataxia (h2 = 0.45, P = 0.0011), migraine
(h2=0.41, P = 0.0138), and hearing impairment (h2=0.40,
P = 0.0050) (Table 2). Diabetes, visual acuity, and
encephalopathy have estimates that are close to signifi-
cance (P < 0.08). These results, which take age-adjusted
blood heteroplasmy, age, and sex into account, provide
good evidence for the presence of nuclear genetic factors
influencing several clinical outcomes in m.3234A>G-
related disease.
For the vast majority of traits, the proportion of vari-
ance that can be attributed to additive genetic factors is
considerably larger than the proportion that can be attrib-
uted to age, heteroplasmy, and sex suggesting that, in
m.3243A>G carriers, nuclear background has a larger
clinical effect than these known risk factors.
Estimates of the contribution of additive genetic fac-
tors to some of the defining features of MELAS, such
as stroke-like episodes and seizures, are particularly
small. However, these traits are much lower in fre-
quency (Fig. 1), reducing the ability of family-based
tests to measure heritability using a family-based study
design.
Psychiatric involvement, migraine, and
encephalopathy are heritable as binary
traits
The variance component methods implemented in
SOLAR assume normally distributed quantitative trait
data. A limitation of our study is that the trait data are
ordered categorical variables and do not all follow a nor-
mal distribution. To address this issue, we also calculated
heritabilities considering the traits as binary variables
(Table 3). The heritability estimate for psychiatric
involvement remains significant (h2 = 0.55, P = 0.0016),
and for migraine (h2 = 0.77, P = 0.0104) and
encephalopathy (h2 = 0.64, P = 0.0408), the estimates are
greater for the binary trait. This may be due to a stricter
definition of the phenotypes, with milder cases coded as
unaffected in the binary model. Heritability estimates for
cerebellar ataxia, cognition, and hearing impairment are
no longer significant, but this is not surprising given the
loss of information due to converting NMDAS scores to
binary traits and may be due to incorrectly assigning
milder individuals an unaffected status.
Genetic correlation provides evidence for a
shared genetic etiology
To determine the extent to which the heritability of traits
is caused by shared genetic factors, a bivariate model was
used to calculate the estimated genetic correlation
between traits. There is significant genetic correlation
between cerebellar ataxia and psychiatric involvement
(rhoG ~ 0.70, SE = 0.22, P = 0.0081), cerebellar ataxia
and migraine (rhoG ~ 0.72, SE = 0.32, P = 0.0312),
encephalopathy and migraine (rhoG ~ 0.80, SE = 0.27,
P = 0.0340), and cognition and hearing (rhoG ~ 0.61,
SE = 0.25, P = 0.0170). This implies that these traits
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share a genetic etiology; that is, they may be influenced
by variations in the same genes and is not surprising,
given the role of the nervous system in these traits and
the increasing evidence of pleiotropy in complex traits31,32
Due to a reduction in power when using a bivariate
model, we cannot exclude the possibility of shared genetic
etiology between other pairs of traits.
Discussion
The underlying cause of the extensive clinical heterogene-
ity associated with m.3243A>G-related mitochondrial dis-
ease remains poorly understood. Given the heteroplasmic
nature of this pathogenic variant and the progressive nat-
ure of disease, it was not unreasonable to hypothesize that
heteroplasmy level and age explain some of this variance,
although previous studies have only explained a small
proportion.12,14 In this study, we show that hearing
impairment, diabetes, and cerebellar ataxia are the traits
that are best explained by these factors, but pseudo-R2
values are low for all traits studied, ranging from 0.02
(psychiatric involvement, migraine, and gastrointestinal
disturbance) to 0.17 (hearing impairment), leaving a con-
siderable amount of variance unexplained. Notably,
pseudo-R2 values for traits characteristic of the MELAS
phenotype lie between 0.14 (encephalopathy) and 0.07
(stroke-like episodes and seizures). Thus, predicting
which patients are likely to develop severe disease using
these risk factors is almost impossible.
Using a pedigree-based study design, we have shown
that additive genetic factors play a much larger role in
determining the phenotypic outcome in m.3243A>G
Figure 3. McFadden’s pseudo-R2 values and odds ratios (with 95% confidence intervals) showing the effect of age and heteroplasmy level
(decades for age and 10% change in level for heteroplasmy) on the risk of developing specific m.3243A>G-related disease traits. Odds ratios with
confidence intervals that do not cross the dotted line at OR = 1 are significant at the P < 0.05 level. The total number of patients included in the
analyses ranges from 193 to 212.
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carriers than heteroplasmy level, age, and sex. Moderate
to large estimates of heritability were observed for psychi-
atric involvement, cerebellar ataxia, migraine, cognition,
and hearing impairment (h2 range = 0.40–0.76). This is
good evidence for the presence of nuclear factors influ-
encing the clinical phenotype in m.3243A>G-related dis-
ease. Pedigrees containing m.3243A>G carriers with
similar phenotypic presentations have been previously
described, suggesting the presence of a heritable factor
influencing phenotype.17,33 However, this is the first study
to clearly demonstrate the presence of a nuclear effect in
a whole cohort and to quantify this with heritability esti-
mates.
We have confirmed the well-recognized clinical hetero-
geneity associated with m.3243A>G using the NMDAS
scale. As expected, features of the MELAS phenotype (sei-
zures, encephalopathy, and stroke-like episodes) are
strongly correlated and a moderate correlation is seen
between hearing and deafness, features of maternally
inherited diabetes and deafness (MIDD).7,14,30,34 Less
anticipated were the moderate to strong correlations with
cerebellar ataxia; notably for myopathy, dysphonia–dysar-
thria, and hearing impairment. This perhaps indicates
overall neurodegeneration but may point toward a key
role of the cerebellum in the pathology of m.3243A>G-
related disease, further supported by genetic correlations
between cerebellar ataxia and psychiatric involvement and
cerebellar ataxia and migraine, suggesting shared genetic
etiology for these traits. Our observations are in-line with
previous reports describing prominent atrophy within the
cerebellum of m.3243A>G patients both with and without
stroke-like episodes.35,36 Whilst migraine and diabetes
only correlate with a small number of other traits, sug-
gesting that the underlying aetiologies of these traits are
different and may be more heavily influenced by factors
such as nuclear background and environmental factors,
the correlation between migraine and gastrointestinal dis-
turbance is intriguing. It is tempting to hypothesize that a
similar biological mechanism may underlie these traits
and could involve smooth muscle, given recent evidence
that migraine-associated genetic variants are enriched for
genes involved in smooth muscle function.37 However, we
should be cautious not to over-interpret statistical
correlations.
The correlations between psychiatric disturbance and
seizures, encephalopathy, and stroke-like episodes
(r ~ 0.24–0.34) were also intriguing. Upon further
Table 2. Estimates of the proportion of trait variance due to known
covariates (age-adjusted blood heteroplasmy, age, and sex) and addi-
tive genetic factors (heritability).
Trait
Number
of cases h2 SE P value
Proportion of
variance due
to covariates
Psychiatric
involvement
214 0.76 0.21 0.0003 0.03
Cerebellar ataxia** 213 0.45 0.16 0.0011 0.40
Migraine 214 0.41 0.19 0.0138 0.04*
Cognition 205 0.46 0.17 0.0021 0.06
Neuropathy** 213 0.14 0.19 0.2257 0.09
Dysphonia–
dysarthria**
213 0.18 0.15 0.0992 0.18*
Seizures** 214 0.05 0.13 0.3605 0.10
Encephalopathy** 214 0.18 0.12 0.0624 0.08
Stroke-like
episodes**
214 0.12 0.13 0.1509 0.07
Visual acuity** 210 0.31 0.21 0.0570 0.06
Ptosis 213 0.20 0.21 0.1489 0.11*
CPEO** 213 0.28 0.22 0.0926 0.11
Hearing
impairment
214 0.40 0.16 0.0050 0.36
Gastrointestinal
disturbance
214 0.06 0.19 0.3770 0.13*
Myopathy 213 0.07 0.17 0.3350 0.19*
Diabetes 214 0.28 0.19 0.0715 0.27
Cardiovascular
involvement
193 0.09 0.19 0.3050 0.18
Total variance is equal to one.
*Sex included in the model where P < 0.1.
**Square root of trait used to normalize the residuals. Bold indicates
significant heritabilities (P <0.05).
Table 3. Binary trait heritability (h2).
Trait
Number
of cases h2 SE P value
Kullback-
Leibler R2
Psychiatric
involvement
214 0.55 0.19 0.0016 0.01**
Cerebellar ataxia 213 0.46 0.37 0.0957 0.19
Migraine 214 0.77 0.33 0.0104 0.05*
Cognition 205 0.46 0.91 0.1023 0.04
Dysphonia–dysarthria 213 0.13 0.53 0.4019 0.15
Encephalopathy 214 0.64 0.36 0.0408 0.10
Stroke-like episodes 214 0.51 0.49 0.1423 0.12
Visual acuity 210 0.26 0.26 0.2130 0.04
Ptosis 213 0.15 0.39 0.3510 0.08*
CPEO 213 0.47 0.52 0.2102 0.06
Hearing impairment 214 0.52 0.38 0.0886 0.23*
Diabetes 214 0.37 0.35 0.1462 0.22
Cardiovascular
involvement
193 0.08 0.36 0.4066 0.13
Converting NMDAS scores to a binary trait leads to a loss of informa-
tion and, as a result, it was not possible to calculate heritabilities for
neuropathy, seizures, gastrointestinal disturbance, or myopathy. Kull-
back-Leibler R2 represents the information gained by including hetero-
plasmy level and age (*and sex, where P < 0.1) in the model.
**Psychiatric involvement was analyzed as a quasi-quantitative trait to
avoid numerical problems in SOLAR, and therefore, this figure repre-
sents the proportion of variance due to covariates. Bold indicates sig-
nificant heritabilities (P < 0.05).
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investigation, we discovered that of the 22 patients in our
cohort who have both encephalopathy and moderate to
severe psychiatric disturbance (NMDAS≥3), 19 have evi-
dence of encephalopathy documented before or within
the same 12-month period as the onset of these psychi-
atric symptoms. Therefore, psychosis may be linked to
dysfunctional brain and such a hypothesis is supported by
the well-documented existence of postictal psychosis in
epilepsy patients.38 We were not able to replicate the pre-
viously reported association between stroke-like episodes
and sex, although our data do show a similar trend.14
The over-representation of males with stroke-like episodes
could be the result of ascertainment bias; we actively trace
family members who carry the m.3243A>G variant result-
ing in the recruitment of more mildly affected females.
However, the higher male penetrance for pathogenic
mtDNA variants associated with Leber hereditary optic
neuropathy is well documented and we do see a signifi-
cant effect of sex for both ptosis and myopathy, support-
ing the role of sex in m.3243A>G-related disease.14,39
Although we estimate low heritabilities for stroke-like
episodes and seizures, we cannot exclude the possibility
that nuclear factors are involved in these severe pheno-
types. A number of our pedigrees were identified due to a
diagnosis of MELAS in one family member, but many of
these could not be recruited to the study due to the often
fatal nature of MELAS, limiting our ability to measure
heritability for these traits. Within this context, it is inter-
esting to note that encephalopathy, a sign of substantial
brain disease, is heritable when considered as a binary
trait (h2 = 0.64, P = 0.0408). Continued pedigree recruit-
ment and long-term follow-up is needed to produce more
accurate estimates.
The demonstration of nuclear background influencing
clinical heterogeneity in m.3243A>G-related disease has
far-reaching implications. First, it opens up the possibility
of identifying these factors and, with rapid DNA sequenc-
ing technologies, ever-expanding well-characterized patient
cohorts and pedigree tracing, this may be within our sights.
Given the pedigrees that are available for study, areas of the
nuclear genome responsible for these high heritabilities
could be identified using genetic linkage analysis, which
has the advantage of being able to detect effects due to rare
and common variants, along with family-specific effects.40
This would allow us to determine whether the nuclear
effect is caused by many small effect loci, a small number
with larger effect, or a combination of the two. Causal vari-
ants in these linked regions could be identified by next-
generation sequencing, and their role in pathogenesis con-
firmed using molecular biochemical techniques. Identifying
interactions between nuclear variation and m.3243A>G
should allow the development of more accurate tools for
disease prognosis and progression, as well as having
translational impact through the provision of accurate
genetic advice to families considering reproductive options.
Understanding these complex interactions and how they
lead to disease is particularly pertinent given the recent
development of pronuclear transfer (PNT) in the preven-
tion of transmission of mtDNA mutations.41 Indeed,
nuclear factors involved in m.3243A>G-related disease may
also impact other clinically heterogeneous mitochondrial
diseases such as those caused by m.8344A>G and muta-
tions within POLG.42,43
We acknowledge that there are caveats to the interpreta-
tion of our data. Firstly, using easily sampled tissues such
as blood or urine to detect the level of heteroplasmy does
not truly represent the heteroplasmy levels present in tis-
sues that are the most severely affected by m.3243A>G-
related disease. Although blood m.3243A>G heteroplasmy
levels decline over time, age-corrected blood heteroplasmy
level is just as good as muscle level at predicting overall dis-
ease progression and is a better predictor than urine level,
which is affected by sex and is more variable (unpublished
data). The mechanisms involved in the establishment of the
tissue distribution of heteroplasmy levels and mtDNA copy
number levels are poorly understood, although nuclear fac-
tors may play a role and could represent one mechanism by
which nuclear variation modifies phenotype.17
Second, we have used the NMDAS to define
m.3243A>G-related traits and this should be considered
when interpreting our results. For instance, psychiatric dis-
turbance can range from mild (e.g., reactive depression) to
severe (e.g., bipolar disorder and psychosis), and is likely to
represent a number of different conditions with different
aetiologies. Similarly, the NMDAS migrainous question does
not distinguish between different types of migrainous head-
ache and impairment of visual acuity could represent a
number of different pathologies, including pigmentary
retinopathy and optic atrophy. Therefore, the underlying
genetic architecture influencing these traits is also likely to
be heterogeneous. In addition, the NMDAS scale for cogni-
tion primarily assesses processing speed and pre-morbid IQ,
known to decline in patients with mitochondrial disease,
and we have not corrected this for confounders such as edu-
cational attainment. However, the NMDAS is clinically vali-
dated and widely used and is the only currently available
tool for this type of analysis. In further support of its use,
our heritability estimates fall within population-based esti-
mates for migraine (28–65%),44 age-related sensory hearing
loss (25–55%)45, and cognition (28–62%, in patients with
type 2 diabetes).46 Population-based heritability estimates
for major depression are 31–42%.47 Our estimate for psychi-
atric disturbance in m3243A>G-related disease is larger than
this; however, estimates are higher for more severe psychi-
atric disorders such as schizophrenia (64–67%) and bipolar
disorder (59–62%), consistent with our results.48,49
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Finally, although the variance component methods
implemented in SOLAR estimate the proportion of vari-
ance due to additive genetic factors using the degree of
relatedness between individuals, heritability estimates may
be inflated due to increased shared environment between
more closely related individuals. Even with high heritabil-
ities, the nuclear genetic factors may not be easy to iden-
tify. Our patient cohort is large and well characterized for
such a rare disease, but sample size could be a limitation.
Most genetic associations in common disease confer a rel-
atively small effect on phenotype with odds ratios of 1.2–
1.5, their detection requiring large sample sizes.50
However, there are exceptions to this, for example, poly-
morphisms in CFH contributing to age-related macular
degeneration, and rare variants with higher penetrance
and could be detected using a family-based approach.51
This study identifies nuclear variation as a key contrib-
utor to the vast clinical heterogeneity seen in
m.3243A>G-related disease, opening up the possibility of
identifying these factors and improving our understand-
ing of this complex mitochondrial disease. It also high-
lights the benefits of pedigree tracing, not only to
improve patient care and the rate of diagnosis but also to
better understand disease etiology. The molecular mecha-
nisms underlying m.3243A>G-associated traits are likely
to involve a complex interplay between m.3243A>G
mutant load, mtDNA copy number, nuclear genetic fac-
tors, epigenetics, and environmental exposures. The next
challenge is to identify these nuclear risk factors in order
to better understand the cellular and tissue-specific effects
in m.3243A>G-related disease and provide improved esti-
mates of disease prognosis and counseling to patients.
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